Skip to content
Subscriber Only

CSL Said in Talks to Buy $8.6 Billion Swiss Drug Maker Vifor

A sign for the requirement of a Covid-19 vaccination certificate outside a Subway Restaurants fast-food outlet in Bern, Switzerland, on Thursday, Sept. 16, 2021.

A sign for the requirement of a Covid-19 vaccination certificate outside a Subway Restaurants fast-food outlet in Bern, Switzerland, on Thursday, Sept. 16, 2021.

Photographer: Stefan Wermuth/Bloomberg
Updated on

Australian biotech company CSL Ltd. is in talks with Vifor Pharma AG over an acquisition of the Swiss-based drug maker, according to people familiar with the matter.

CSL is working on financing a possible takeover of Vifor, which has a market value of 8 billion Swiss francs ($8.6 billion), the people said, asking not to be identified discussing confidential information.